LB Pharmaceuticals Inc.

LBRX Nasdaq SEC CIK 1691082
Follow LB Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$59.1M −1561% vs same quarter last year
EPS, diluted −$1.79 −193.4% vs same quarter last year
Operating cash flow −$64.3M −1806.1% vs same quarter last year
Net income by quarter
−$5.1M
−$5.3M
−$4.9M
−$3.6M
−$11.5M
−$19.1M
−$51.6M
−$59.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing